Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Launched by HOFFMANN-LA ROCHE · Oct 11, 2020
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The TAPISTRY study is a clinical trial designed to test new treatments for patients with advanced solid tumors that cannot be surgically removed or have spread to other parts of the body. This trial focuses on using targeted therapies or immunotherapy, which are types of treatments that help the body's immune system fight cancer or target specific genetic changes in the tumors. Participants will be chosen for the study based on the genetic profile of their cancer, identified through a special test called next-generation sequencing, which helps determine the best treatment plan for each individual.
To be eligible for the trial, participants must have a confirmed diagnosis of advanced cancer, measurable disease, and a life expectancy of at least 8 weeks. They should also be recovering well from any recent cancer treatments and meet specific health criteria. Throughout the study, participants will receive their assigned treatment and be closely monitored for how well the treatment works and any side effects. This trial is currently recruiting patients of all ages and genders, and it aims to find effective and personalized treatment options for those facing challenging cancer diagnoses.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically or cytologically confirmed diagnosis of advanced and unresectable or metastatic solid malignancy
- • Measurable disease as defined by RECIST v1.1, RANO, or INRC
- • Performance status as follows: Participants aged ≥ 18 years: Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; Participants aged 16 to \< 18 years: Karnofsky score ≥ 50%; Participants aged \< 16 years: Lansky score ≥ 50%
- • For participants aged ≥ 18 and \< 18 years: adequate hematologic and end-organ function
- • Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment
- • Adequate recovery from most recent systemic or local treatment for cancer
- • Life expectancy ≥ 8 weeks
- • Ability to comply with the study protocol, in the investigator's judgment
- • For female participants of childbearing potential: Negative serum pregnancy test ≤ 14 days prior to initiating study treatment, agreement to remain abstinent or use single or combined contraception methods that result in a failure rate of \< 1% per year for the period defined in the cohort-specific inclusion criteria; and agreement to refrain from donating eggs during the same period
- • For male participants: Willingness to remain abstinent or use acceptable methods of contraception as defined in the cohort-specific inclusion criteria
- • In addition to the general inclusion criteria above, participants must meet all of the cohort-specific inclusion criteria for the respective cohort
- Exclusion Criteria:
- • Current participation or enrollment in another therapeutic clinical trial
- • Any anticancer treatment within 2 weeks or 5 half-lives prior to start of study treatment
- • Whole brain radiotherapy within 14 days prior to start of study treatment
- • Stereotactic radiosurgery within 7 days prior to start of study treatment
- • Pregnant or breastfeeding, or intending to become pregnant during the study
- • History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study or confounds the ability to interpret data from the study
- • Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment
- • Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or higher), myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina
- • History of another active cancer within 5 years prior to screening that may interfere with the determination of safety or efficacy of study treatment with respect to the qualifying solid tumor malignancy
- • In addition to the general exclusion criteria above, in order to be enrolled in a treatment cohort of the study, participants must not meet any of the cohort-specific exclusion criteria
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Lebanon, New Hampshire, United States
Bordeaux, , France
Lyon, , France
Lille, , France
Parkville, Victoria, Australia
Randwick, New South Wales, Australia
New York, New York, United States
Madrid, , Spain
Ocala, Florida, United States
Memphis, Tennessee, United States
Madrid, , Spain
Duarte, California, United States
Portland, Oregon, United States
Detroit, Michigan, United States
Cincinnati, Ohio, United States
Albuquerque, New Mexico, United States
Milwaukee, Wisconsin, United States
Omaha, Nebraska, United States
Gainesville, Florida, United States
Saint Louis, Missouri, United States
Aurora, Colorado, United States
Tacoma, Washington, United States
Gent, , Belgium
Sacramento, California, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Gainesville, Florida, United States
Los Angeles, California, United States
San Francisco, California, United States
Woolloongabba, Queensland, Australia
Ann Arbor, Michigan, United States
Toronto, Ontario, Canada
Bruxelles, , Belgium
Charleroi, , Belgium
Leuven, , Belgium
Shanghai, , China
Tianjin, , China
Christchurch, , New Zealand
Porto, , Portugal
Singapore, , Singapore
Singapore, , Singapore
Barcelona, , Spain
Madrid, , Spain
Madrid, , Spain
Valencia, , Spain
Ottawa, Ontario, Canada
Bronx, New York, United States
Houston, Texas, United States
Shatin, , Hong Kong
Los Angeles, California, United States
Valencia, , Spain
Athens, Georgia, United States
Newport Beach, California, United States
Seoul, , Korea, Republic Of
Taichung, , Taiwan
Gainesville, Florida, United States
Tokyo, , Japan
Athens, Georgia, United States
Ocala, Florida, United States
Glasgow, , United Kingdom
Santa Monica, California, United States
Edegem, , Belgium
Seongnam Si, , Korea, Republic Of
Seoul, , Korea, Republic Of
Melbourne, Victoria, Australia
Pretoria, , South Africa
Marseille, , France
Fort Worth, Texas, United States
Manchester, , United Kingdom
Johannesburg, , South Africa
Beijing, , China
Göttingen, , Germany
Seongnam Si, , Korea, Republic Of
Seoul, , Korea, Republic Of
Shanghai, , China
Madrid, , Spain
Tel Aviv, , Israel
Milano, Lombardia, Italy
Billings, Montana, United States
Cincinnati, Ohio, United States
New Brunswick, New Jersey, United States
Charlotte, North Carolina, United States
Bordeaux, , France
Esplugues De Llobregas, Barcelona, Spain
Lille, , France
Milano, Lombardia, Italy
Torino, Piemonte, Italy
Utrecht, , Netherlands
Dallas, Texas, United States
København ø, , Denmark
Scarborough, Maine, United States
Chiba, , Japan
Petach Tikva, , Israel
Sao Paulo, , Brazil
København ø, , Denmark
Freiburg, , Germany
Hannover, , Germany
Singapore, , Singapore
Sao Paulo, Sp, Brazil
Newark, Delaware, United States
Lafayette, Indiana, United States
Omaha, Nebraska, United States
Xi'an, , China
Aarhus N, , Denmark
Johannesburg, , South Africa
Melbourne, Victoria, Australia
Napoli, Campania, Italy
Gyeonggi Do, , Korea, Republic Of
München, , Germany
Ulm, , Germany
Changchun, , China
Seongnam Si, , Korea, Republic Of
Gdansk, , Poland
Jerusalem, , Israel
Las Vegas, Nevada, United States
Heidelberg, , Germany
Madrid, , Spain
Haifa, , Israel
East Setauket, New York, United States
Osaka, , Japan
Aalborg, , Denmark
Porto Alegre, Rs, Brazil
London, , United Kingdom
Germantown, Tennessee, United States
Leesburg, Pennsylvania, United States
Tacoma, Washington, United States
Sao Paulo, Sp, Brazil
Brescia, Lombardia, Italy
Billings, Montana, United States
Tyler, Texas, United States
Madrid, , Spain
Dallas, Texas, United States
Toronto, Ontario, Canada
Tainan, , Taiwan
Sutton, , United Kingdom
Saint Louis, Missouri, United States
Taipei City, , Taiwan
Montreal, Quebec, Canada
Siena, Toscana, Italy
Austin, Texas, United States
London, , United Kingdom
Ramat Gan, , Israel
Darlinghurst, New South Wales, Australia
Goodyear, Arizona, United States
Zion, Illinois, United States
Vancouver, British Columbia, Canada
Hamburg, , Germany
Toulouse, , France
Daphne, Alabama, United States
Heilbronn, , Germany
Porto Alegre, Rio Grande Do Sul, Brazil
Changchun City, , China
Madrid, , Spain
Aarhus N, , Denmark
Tiwi, Northern Territory, Australia
Bronx, New York, United States
Roma, Lazio, Italy
Saint Louis Park, Minnesota, United States
Barcelona, , Spain
San Francisco, California, United States
Toronto, , Canada
Haifa, , Israel
Aalborg, , Denmark
Aurora, Colorado, United States
Hong Kong, , Hong Kong
Essen, , Germany
Pretoria, , South Africa
Bellinzona, , Swaziland
Miami, Florida, United States
Horsham, Pennsylvania, United States
Würzburg, , Germany
Darlinghurst, New South Wales, Australia
Brescia, Lombardia, Italy
Warszawa, , Poland
London, Ontario, Canada
Beijing, , China
Tainan, , Taiwan
Auckland, , New Zealand
Madrid, , Spain
Germantown, Tennessee, United States
Taoyuan County, , Taiwan
Lyon, , France
Zhongzheng Dist., , Taiwan
Porto Alegre, Rs, Brazil
Madrid, , Spain
Moskva, Moskovskaja Oblast, Russian Federation
Chengdu City, , China
San Juan, , Puerto Rico
Shanghai City, , China
Shatin, , Hong Kong
San Juan, , Puerto Rico
Zürich, , Switzerland
Broomall, Pennsylvania, United States
Taipei City, , Taiwan
Los Angeles, California, United States
Newark, Delaware, United States
Boise, Idaho, United States
Silver Spring, Maryland, United States
Albuquerque, New Mexico, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Greenville, South Carolina, United States
Leesburg, Virginia, United States
Sao Paulo, Sp, Brazil
Beijing City, , China
Villejuif, , France
Mönchengladbach, , Germany
Roma, Lazio, Italy
Firenze, Toscana, Italy
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Basel, , Switzerland
Bern, , Switzerland
City Of Johannesburg, , South Africa
Tyler, Texas, United States
Seoul, , Korea, Republic Of
London, , United Kingdom
Barcelona, , Spain
Lyon, , France
Vancouver, British Columbia, Canada
Singapore, , Singapore
Sant Andreu De La Barca, Barcelona, Spain
Bellinzona, , Switzerland
St Petersburg, Sankt Petersburg, Russian Federation
Utrecht, , Netherlands
Singapore, , Singapore
Tiwi, Northern Territory, Australia
Manchester, , United Kingdom
Bern, , Switzerland
Taichung, , Taiwan
Billings, Montana, United States
Austin, Texas, United States
Moskva, Moskovskaja Oblast, Russian Federation
Sao Paulo, São Paulo, Brazil
Porto, , Portugal
Barcelona, , Spain
Petach Tikva, , Israel
Milano, Lombardia, Italy
Torino, Piemonte, Italy
Roma, Lazio, Italy
Milano, Lombardia, Italy
Taoyuan County, , Taiwan
Sao Paulo, São Paulo, Brazil
Warszawa, , Poland
Charleroi, , Belgium
Tel Aviv, , Israel
Heilbronn, , Germany
Zhongzheng Dist., , Taiwan
München, , Germany
Port Jefferson Station, New York, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Sao Paulo, São Paulo, Brazil
Vancouver, British Columbia, Canada
London, Ontario, Canada
Toronto, Ontario, Canada
Shanghai City, , China
Shanghai, , China
Göttingen, , Germany
Ulm, , Germany
Würzburg, , Germany
Roma, Lazio, Italy
Firenze, Toscana, Italy
Gda?Sk, , Poland
Charleroi, , Belgium
Zion, Illinois, United States
Freiburg Im Breisgau, , Germany
Heidelberg, , Germany
Moscow, , Russian Federation
Moscow, , Russian Federation
Saint Petersburg, , Russian Federation
Johannesburg, , South Africa
Sao Paulo, , Brazil
Sao Paulo, , Brazil
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials